Brigid Bio

What Brigid Bio does

Brigid Bio is a pre-revenue biotechnology spinout from the University of Aberdeen, incorporated in 2025 and headquartered at Foresterhill Health Campus in Aberdeen, Scotland. The company develops first-in-class fully human monoclonal antibody (mAb) immunotherapies for the treatment of invasive fungal infections (IFIs), an indication associated with 3 million global deaths annually and 40-80% mortality under best-available care, unchanged for two decades. Its pipeline targets fungal-specific cell wall remodelling proteins with no human homologues, deliberately chosen because they are conserved across Candida and Aspergillus species and overexpressed in drug-resistant clinical isolates.

The company's core technical asset is a patented drug discovery platform that integrates proteomics and transcriptomics to identify cell wall markers critical for pathogen survival during infection and under antifungal pressure, followed by guided epitope selection and advanced antibody engineering to generate fully human mAbs. Lead candidates have demonstrated pan-fungal binding, higher potency than competitor sugar-binding molecules, synergy with standard-of-care echinocandins and azoles, enhanced binding in drug-resistant strains, and efficacy in clinically predictive mouse models of disseminated candidiasis in both immunocompetent and immunocompromised hosts. Differentiation claims include a once-monthly dosing interval enabled by extended biological half-life, the absence of drug-drug interactions that would allow concomitant cancer chemotherapy, and immune evasion disruption via macrophage-engulfment overexpression of the target.

Brigid Bio's revenue model is structured around future out-licensing and co-development partnerships with pharmaceutical and biotech counterparties; the company itself states that as a pre-revenue R&D-stage developer it has no commercial products, pricing, or distribution. To date, the firm has been financed through non-dilutive mechanisms, including INCATE Stage II grant selection and the Scottish EDGE headline award (drawn from a £1.5M pool shared by 31 startups), and it has built out a manufacturing pathway through a development agreement with Dyadic International for animal-free recombinant protein production. The commercial target customers are enterprise pharmaceutical partners, while the clinical end-users are immunocompromised patients undergoing cancer therapy, ICU patients, and providers managing multidrug-resistant Candida auris, Candida glabrata, and Aspergillus fumigatus infections.

Name

Brigid Bio

Legal name

Brigid Bio Ltd

Website

https://brigidbio.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Brigid Bio is a University of Aberdeen spinout developing first-in-class fully human monoclonal antibody immunotherapies targeting pan-fungal cell wall proteins to treat life-threatening and drug-resistant invasive fungal infections in immunocompromised and ICU patients.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

Keywords

• Monoclonal antibody therapy
• Antifungal immunotherapy
• Invasive fungal infections
• Biologic therapeutics
• Fungal drug discovery

Headquarters

HQ city

Aberdeen

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Biologic Therapeutics Development: Pre-revenue biotech company developing first-in-class monoclonal antibody immunotherapies for invasive fungal infections. Revenue model anticipated through licensing deals, co-development partnerships with pharmaceutical companies, and eventual product commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Brigid Bio is developing first-in-class, fully human monoclonal antibody (mAb) immunotherapies for the treatment of life-threatening and drug-resistant invasive fungal infections (IFIs). The company's pipeline uses a proprietary drug discovery platform combining proteomics and transcriptomics to identify fungal-specific cell wall targets, and is designed to be used alongside standard-of-care antifungals (echinocandins and azoles) in immunocompromised patients, including those undergoing cancer therapy and ICU patients.

Product overview

Brigid Bio is developing a pipeline of first-in-class human monoclonal antibodies (mAbs) as next-generation immunotherapies for invasive fungal infections. The company's core offering centers on its proprietary drug discovery platform that integrates proteomics and transcriptomics to identify and develop pan-fungal therapeutic antibodies targeting conserved cell wall proteins in Candida and Aspergillus species. These fully human mAbs are designed to work synergistically with standard-of-care antifungals (echinocandins and azoles), offering advantages including no drug-drug interactions, pan-fungal activity, reduced hospital stays (monthly vs daily/weekly dosing), and increased binding efficacy in drug-resistant strains.

Differentiator

Problem solved

Functional benefit

Products and services

• Human Monoclonal Antibodies (mAbs) for Invasive Fungal Infections First-in-class fully human monoclonal antibodies targeting unique fungal cell wall remodelling proteins with no human homologues, intended for the treatment of life-threatening and drug-resistant invasive fungal infections in immunocompromised and ICU patients. Designed for synergistic use with standard-of-care antifungals, with no drug-drug interactions and once-monthly dosing versus daily/weekly administration.

Quantifiable outcome

• 40-80% mortality rate associated with IFIs remains unchanged in 20 years, highlighting urgent unmet need
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core.

• BEAM AlliancecoreStrategic or Co-development Partner · 11 December 2025Brigid Bio joined BEAM Alliance (Brussels Engineers and Architects of the Microbial world) to strengthen the fight against Antimicrobial Resistance. The alliance brings together industry leaders and academic experts to advance innovation in antifungal therapeutics.
• University of AberdeencoreStrategic or Co-development Partner · 28 July 2025Spinout from University of Aberdeen, leveraging world-class scientific expertise from Aberdeen Fungal Group and Scottish Biologics Facility. The company maintains close ties with academic founders.
• Dyadic InternationalcoreStrategic or Co-development Partner · 1 January 2025Development agreement with Dyadic International for animal-free bovine alpha-lactalbumin. This partnership is part of Dyadic's strategy to transition into a commercially driven organization and represents Brigid Bio's engagement in sustainable bio-production methods.
• Aberdeen Fungal GroupcoreStrategic or Co-development Partner · 1 January 2025One of two centres of excellence leveraged by Brigid Bio, providing world-class scientific expertise in fungal research.
• Scottish Biologics FacilitycoreStrategic or Co-development Partner · 1 January 2025One of two centres of excellence leveraged by Brigid Bio, providing capabilities in biologic development.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• F2G (now Shionogi): F2G developed olorofim, a first-in-class antifungal therapeutic for invasive fungal infections including drug-resistant aspergillosis, before being acquired by Shionogi in 2024 for ~$450M. Most directly comparable as a clinical-stage antifungal innovator that successfully exited via pharma partnership — same therapeutic focus and similar licensing playbook that Brigid Bio is pursuing.
• Cidara Therapeutics: Cidara develops antifungal therapeutics including rezafungin (approved FDA 2023) and Cloudbreak antiviral conjugates. Directly comparable as an antifungal-focused biotech developing novel mechanisms against invasive fungal infections in immunocompromised patients.
• Scynexis: Scynexis developed and commercialized brexafungerp (ibrexafungerp), a first-in-class triterpenoid antifungal for refractory invasive fungal infections. Directly comparable as an antifungal innovator targeting the same immunocompromised patient population with novel mechanisms.
• Amplyx Pharmaceuticals (Pfizer): Amplyx developed fosmanogepix, a novel antifungal for invasive infections, acquired by Pfizer in 2021. Directly comparable as an antifungal biotech that exited via major pharma partnership — relevant case study for Brigid Bio's licensing trajectory.
• Basilea Pharmaceutica: Basilea commercializes isavuconazole (Cresemba) and develops other antifungal and antibacterial agents for invasive infections. Comparable as an established commercial-stage antifungal company with hospital-channel expertise relevant to Brigid Bio's eventual commercialization partners.
• Mycovia Pharmaceuticals: Mycovia developed oteseconazole for recurrent vulvovaginal candidiasis and has worked on invasive fungal infection therapeutics. Comparable as an antifungal-focused clinical-stage biotech targeting drug-resistant Candida species.

Regional players

• Novabiotics: Scottish-based Novabiotics develops novel antimicrobial therapies including NP213 (a cationic peptide for fungal nail infections). Comparable as a UK-based anti-infective biotech developing novel antifungal mechanisms, though primarily focused on topical rather than invasive indications.

Emerging players

• Intron Biotechnology: Intron is developing endolysin-based antimicrobial biologics including for S. aureus infections. Comparable as an emerging antimicrobial biologics developer using novel host-targeting mechanisms similar in spirit to Brigid Bio's antibody-based approach.
• ABAC Therapeutics: ABAC is a clinical-stage anti-infective company developing novel antibiotics and antifungals targeting multidrug-resistant pathogens. Comparable as an emerging antimicrobial biotech addressing the same WHO/CDC priority pathogen landscape.

Others

• Dyadic International: Dyadic's C1 protein production platform is being used by Brigid Bio (announced 2025 development agreement) for animal-free bio-production. Relevant as a manufacturing/infrastructure partner rather than competitor — illustrates Brigid Bio's emerging CMC strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/brigid-bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Brigid Bio